# Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

> **NCT07695207** · PHASE3 · RECRUITING · sponsor: **SANGMYUNG innovation** · enrollment: 266 (estimated)

## Conditions studied

- Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** SMZ1
- **DRUG:** SMZ1 Placebo

## Key facts

- **NCT ID:** NCT07695207
- **Lead sponsor:** SANGMYUNG innovation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-12
- **Final completion:** 2028-07
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695207, "Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07695207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*